|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 594.32 USD | +1.59% |
|
+12.61% | -16.57% |
| 05-16 | A Rally with Caveats |  |
| 05-15 | Regeneron Pharmaceuticals Wins $406.8 Million Antirust Verdict Against Amgen | MT |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last days
Enjoy this offer
* See conditions on site
| Capitalization | 62.8B 56.12B 52.41B 47.21B 87.63B 5,373B 97.97B 613B 240B 2,438B 236B 231B 9,114B | P/E ratio 2025 * |
20.1x | P/E ratio 2026 * | 17.1x |
|---|---|---|---|---|---|
| Enterprise value | 53.46B 47.77B 44.62B 40.19B 74.6B 4,574B 83.4B 522B 204B 2,075B 201B 196B 7,759B | EV / Sales 2025 * |
3.97x | EV / Sales 2026 * | 3.5x |
| Free-Float |
77.36% | Yield 2025 * |
0.48% | Yield 2026 * | 0.51% |
More valuation ratios
* Estimated data
More news
Last Transcript: Regeneron Pharmaceuticals, Inc.
More recommendations
More press releases
More news
| 1 day | +1.59% | ||
| 1 week | +12.61% | ||
| Current month | -0.74% | ||
| 1 month | +5.53% | ||
| 3 months | -11.77% | ||
| 6 months | -21.47% | ||
| Current year | -16.57% |
| 1 week | 535.29 |  | 595.19 |
| 1 month | 520.5 | | 615.61 |
| Current year | 520.5 | | 748.29 |
| 1 year | 520.5 | | 1,211.2 |
| 3 years | 520.5 | | 1,211.2 |
| 5 years | 441 | | 1,211.2 |
| 10 years | 271.37 | | 1,211.2 |
| Manager | Title | Age | Since |
|---|---|---|---|
| President | 65 | 2000-12-31 | |
| Chief Executive Officer | 72 | 1988-01-07 | |
| Director of Finance/CFO | 54 | 2024-02-04 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 72 | 2023-06-08 | |
Michael Brown
BRD | Director/Board Member | 84 | 1991-05-31 |
Joseph Goldstein
BRD | Director/Board Member | 84 | 1991-05-31 |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +1.59% | +12.61% | -39.50% | -10.97% | 62.8B | ||
| +3.83% | +1.69% | +48.40% | +67.97% | 34.32B | ||
| +1.16% | -1.56% | +32.13% | +64.80% | 24.7B | ||
| -0.05% | +3.89% | +36.66% | -38.25% | 24.23B | ||
| +0.47% | 0.00% | +2.38% | -41.95% | 22.3B | ||
| +3.38% | -0.38% | +437.61% | +2,151.89% | 17.73B | ||
| +1.34% | +4.67% | +175.01% | +216.84% | 12.41B | ||
| -1.86% | +25.52% | +117.12% | +119.43% | 12.38B | ||
| -1.26% | +1.95% | +67.50% | -56.63% | 12.24B | ||
| +2.01% | +0.15% | -35.28% | -37.10% | 12.23B | ||
| Average | +1.06% | +4.79% | +84.20% | +243.60% | 23.53B | |
| Weighted average by Cap. | +1.41% | +5.45% | +53.92% | +180.81% |
| 2025 * | 2026 * | |
|---|---|---|
| Net sales | 13.47B 12.04B 11.24B 10.13B 18.8B 1,152B 21.01B 132B 51.45B 523B 50.52B 49.47B 1,955B | 14.3B 12.78B 11.93B 10.75B 19.95B 1,223B 22.31B 140B 54.62B 555B 53.63B 52.52B 2,075B |
| Net income | 3.14B 2.81B 2.62B 2.36B 4.38B 269B 4.9B 30.68B 11.99B 122B 11.78B 11.53B 456B | 3.55B 3.17B 2.97B 2.67B 4.96B 304B 5.54B 34.7B 13.57B 138B 13.33B 13.05B 516B |
| Net Debt | -9.34B -8.35B -7.79B -7.02B -13.03B -799B -14.57B -91.23B -35.67B -363B -35.03B -34.3B -1,356B | -12.74B -11.38B -10.63B -9.58B -17.78B -1,090B -19.87B -124B -48.66B -494B -47.78B -46.78B -1,849B |
More financial data
* Estimated data
Employees
15,158
Calendar
05-19
- Détachement de
| Date | Price | Change | Volume |
|---|---|---|---|
| 25-05-16 | 594.32 $ | +1.59% | 936,922 |
| 25-05-15 | 584.99 $ | +2.39% | 1,302,126 |
| 25-05-14 | 571.36 $ | -0.49% | 1,664,485 |
| 25-05-13 | 574.16 $ | -0.26% | 1,149,899 |
| 25-05-12 | 575.63 $ | +9.07% | 1,898,394 |
Delayed Quote Nasdaq, May 16, 2025 at 04:00 pm
More quotes
Sell
Buy
Mean consensus
BUY
Number of Analysts
26
Last Close Price
594.32USD
Average target price
797.21USD
Spread / Average Target
+34.14%
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- REGN Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition